75 results
8-K
EX-10.2
MACA
Moringa Acquisition Corp - Ordinary Shares
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
, acknowledges, represents, warrants and agrees that it has conducted its own independent review and analysis of, and, based thereon, has formed … an independent judgment concerning, the business, assets, condition, operations and prospects of, the Company and the Transactions as it and its Representatives
8-K
EX-2.1
MACA
Moringa Acquisition Corp - Ordinary Shares
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
as individual independent contractors or directors, or with respect to which any Group Company has or could have any direct or indirect liability … and other receivables and inventory are recorded accurately. The Company has not identified or been made aware of, and has not received from its independent
8-K
EX-10.3
MACA
Moringa Acquisition Corp - Ordinary Shares
3 Apr 24
Entry into a Material Definitive Agreement
11:22am
expenses;
(D) reasonable fees and disbursements of counsel for the Company;
(E) reasonable fees and disbursements of all independent registered … ” letter from the Company’s independent registered public accountants in the event of an Underwritten Registration, in customary form and covering
8-K
EX-10.3
t6153b6
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
8-K
EX-2.1
j92 4lc4u5uzcr
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
8-K
EX-10.2
uxczj
26 Feb 24
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
5:29pm
PRER14A
gcj1lqk1d88i3ox
24 Jul 23
Preliminary revised proxy
4:45pm
PRE 14A
ytpz20j3bz
15 Dec 22
Preliminary proxy
5:18pm